Written by: Lu de Souza, Oracle Medical Officer and Christy Dueck, Vice President and Global Head Cerner Learning Health Network and Health System Activation
The continued maturation of decentralized clinical trials (DCTs) has given researchers the ability to collect securely real-world data about patients as they go about their daily routines. This broader access provides us with new, more accurate ways to measure outcomes.
To successfully operationalize at scale and meet sponsor expectations, it is paramount for organizations to have a modern platform that can collect and streamline the data, analyze it, and provide insights that can help increase the speed and efficiency of clinical trials.
Recently, Oracle waspositioned in the Leaders category of the IDC MarketScape for worldwide life science R&D RWE, RWD, platforms, technologies and consulting services 2023 Vendor Assessment (doc #US51186723, September 2023).
According to the report, “Oracle's breadth and depth of RWD and tools covers the life science's value chain. This relationship with both life science and health systems helps close long-standing gaps in the continuum of care and is one of Oracle's biggest strengths.”
Oracle’s Clinical One platform offers the flexibility to configure and scale for traditional, hybrid, or decentralized trials, while supporting the full range of patient choices. The platform enables universal connectivity, effectively ingesting any data source, format, frequency, and volume associated with an application target.
The IDC MarketScape report evaluated vendors based on detailed surveys and interviews with the vendors, publicly available information, and end-user experiences in an effort to provide an accurate and consistent assessment of each vendor's characteristics, behavior, and capability.
“We believe the IDC MarketScape report and its findings align with our strategic mission to provide a flexible, technology platform that allows life sciences organizations to unify operations and accelerate clinical trials,” said Seema Verma, senior vice president and general manager for Oracle Life Sciences. “We believe this recognition reinforces Oracle’s strategy, which is to advance technology’s impact on the life sciences industry and the patients the industry serves.”
As an industry leader, Oracle is committed to pursuing new advances to stay abreast of scientific breakthroughs, regulatory change, technological advances, and the market forces that affect clinical research.
For more information, visit Oracle Clinical One.